AVTE
NASDAQAerovate Therapeutics Inc.
Latest news
25 items- INSIDERSEC Form 4 filed by Director Fairmount Funds Management Llc4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 4 filed by Director Lavelle Erin4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 4 filed by Director Klein Lawrence Otto4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 4 filed by Director Cain Christopher W.4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 4 filed by Director Dobmeier Eric4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERNew insider Fairmount Funds Management Llc claimed ownership of 3,220,368 shares (SEC Form 3)3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Lavelle Erin3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERNew insider Klein Lawrence Otto claimed ownership of 86,215 shares (SEC Form 3)3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Cain Christopher W.3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Dobmeier Eric3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Balta Elizabeth3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Kocinsky Hetal3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERNew insider King Andrew James claimed ownership of 344,863 shares (SEC Form 3)3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Quick Jonathan3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- INSIDERSEC Form 3 filed by new insider Frohlich Tom3 - Jade Biosciences, Inc. (0001798749) (Issuer)
- SECAerovate Therapeutics Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Leadership Update, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant, Material Modification to Rights of Security Holders, Regulation FD Disclosure8-K - Jade Biosciences, Inc. (0001798749) (Filer)
- INSIDERLarge owner Ra Capital Management, L.P. acquired 1,062,326 shares (SEC Form 4)4 - Jade Biosciences, Inc. (0001798749) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Aerovate Therapeutics Inc.SCHEDULE 13D/A - Jade Biosciences, Inc. (0001798749) (Subject)
- SECAerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)
- SECSEC Form 10-Q filed by Aerovate Therapeutics Inc.10-Q - Aerovate Therapeutics, Inc. (0001798749) (Filer)
- SECAerovate Therapeutics Inc. filed SEC Form 8-K: Other Events8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)
- SECAerovate Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - Aerovate Therapeutics, Inc. (0001798749) (Filer)
- PRAerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals—Aerovate Board of Directors approves 1-for-35 reverse stock split— WALTHAM, Mass., April 21, 2025 /PRNewswire/ -- Aerovate Therapeutics, Inc. (NASDAQ:AVTE) ("Aerovate") today announced that its stockholders have approved the proposed merger (the "Merger") with Jade Biosciences, Inc. ("Jade"), along with all proposals related to the Merger. The proposals were voted upon at Aerovate's special meeting of stockholders held on April 16, 2025 (the "Special Meeting"), including a reverse stock split of Aerovate's common stock to be effected at the discretion of the Board of Directors (the "Board") within the parameters approved by Aerovate's stockholders. On April 18, 2025, the Board approved a fi
- SECSEC Form 425 filed by Aerovate Therapeutics Inc.425 - Aerovate Therapeutics, Inc. (0001798749) (Subject)
- SECSEC Form 425 filed by Aerovate Therapeutics Inc.425 - Aerovate Therapeutics, Inc. (0001798749) (Subject)
AVTE FAQ
7 questionsWhat does Aerovate Therapeutics Inc. do?
Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing drugs that enhance the lives of patients with rare cardiopulmonary disease. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension. The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.Where does AVTE stock trade?
Aerovate Therapeutics Inc. (AVTE) is listed on NASDAQ.What sector and industry is AVTE in?
Aerovate Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Aerovate Therapeutics Inc. go public?
Aerovate Therapeutics Inc. (AVTE) completed its IPO in 2021.What are analysts saying about AVTE?
Aerovate Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: In-line with a $200.00 price target on 2024-06-18.What companies are similar to AVTE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AVTE side-by-side with any of them on Quantisnow.How can I track AVTE on Quantisnow?
Quantisnow aggregates Aerovate Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AVTE to receive live email and push alerts on every new disclosure.